SCHEMBL2483643

SCHEMBL2483643

CCCCCCCCC#CCCO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.56
HMGCR P04035 3/20 0.56
ALDH1A1 P00352 3/20 0.52
LMNA P02545 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TSHR P16473 2/20 0.52
HSD17B10 Q99714 1/20 0.52
RECQL P46063 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47
BLM P54132 1/20 0.47
MCL1 Q07820 1/20 0.47
SELP P16109 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL487444 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL8684335 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL2806902 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL29479496 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL487538 0.97 PTPN7 (0.52) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10959870 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10960337 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10956905 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10962163 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL15283605 0.90 HMGCR (0.59) PTPN7HMGCRALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125614-A1 IONIZABLE CATIONIC LIPIDS AKAGERA MEDICINES, INC. (US) 2026-05-07 US disclosed
US-12606773-B2 Ionizable cationic lipids AKAGERA MEDICINES, INC. (US) 2026-04-21 US disclosed
US-20260077038-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF AKAGERA MEDICINES, INC. (US) 2026-03-19 US disclosed
US-20260069684-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF AKAGERA MEDICINES, INC. (US) 2026-03-12 US disclosed
US-20260055335-A1 IONIZABLE CATIONIC LIPID COMPOUNDS AKAGERA MEDICINES, INC. (US) 2026-02-26 US disclosed
US-12331264-B2 Lipid nanoparticles for delivery of nucleic acids and methods of use thereof AKAGERA MEDICINES, INC. (US) 2025-06-17 US disclosed
CN-119562806-A Lipid nanoparticles for delivery of nucleic acids and methods of use thereof 阿卡格拉医药公司 2025-03-04 CN disclosed
US-20240325525-A1 Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof AKAGERA MEDICINES, INC. (US) 2024-10-03 US disclosed
US-20240309291-A1 IONIZABLE CATIONIC LIPIDS AKAGERA MEDICINES, INC. (US) 2024-09-19 US disclosed
US-12077725-B2 Ionizable cationic lipids AKAGERA MEDICINES, INC. (US) 2024-09-03 US disclosed
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2012-05-17 US disclosed
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2012-05-17 US disclosed
EP-2376432-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2011-10-19 EP disclosed
WO-2010081683-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (DE) 2010-07-22 WO disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 EP disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 EP disclosed
EP-0899286-A1 Vinyl-group-containing dendrimer and curable composition TOYO INK MANUFACTURING CO., LTD. (JP) 1999-03-03 EP disclosed
US-4732756-A INSECTICIDES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1988-03-22 US disclosed
US-4515727-A ANTIALLERGY, ANTINFLAMMATORY SYNTEX (U.S.A.) INC. (US) 1985-05-07 US disclosed
US-4434101-A SLOW REACTING SUBSTANCE OF ANAPHYLAXIS, ANTIALLERGENS HOFFMANN-LA ROCHE INC. (US) 1984-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069684-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF PHOSPHO1, PLTP, SGMS1 PTPN7 3118/4885HMGCR 1721/4885ALDH1A1 4716/4885
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 PTPN7 4686/4885HMGCR 1017/4885ALDH1A1 646/4885
US-12077725-B2 Ionizable cationic lipids PHOSPHO1, LIPA, ABHD16A PTPN7 4600/4885HMGCR 2898/4885ALDH1A1 4099/4885
US-20260077038-A1 LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF PHOSPHO1, LNPK, SGMS2 PTPN7 2678/4885HMGCR 2667/4885ALDH1A1 4782/4885
US-20260125614-A1 IONIZABLE CATIONIC LIPIDS CPT2, NPC1L1, PNPLA2 PTPN7 4752/4885HMGCR 865/4885ALDH1A1 3307/4885
US-12606773-B2 Ionizable cationic lipids NPC1L1, MCOLN1, SLC22A4 PTPN7 3533/4885HMGCR 2057/4885ALDH1A1 2574/4885
US-20260055335-A1 IONIZABLE CATIONIC LIPID COMPOUNDS CD4, LDLR, CD2BP2 PTPN7 4485/4885HMGCR 2789/4885ALDH1A1 2719/4885
US-20240309291-A1 IONIZABLE CATIONIC LIPIDS PHOSPHO1, LIPA, ABHD16A PTPN7 4600/4885HMGCR 2898/4885ALDH1A1 4099/4885
US-20240325525-A1 Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof PHOSPHO1, PTDSS1, PTDSS2 PTPN7 3257/4885HMGCR 4495/4885ALDH1A1 4475/4885
US-12331264-B2 Lipid nanoparticles for delivery of nucleic acids and methods of use thereof ASGR1, LDLR, CD2BP2 PTPN7 2879/4885HMGCR 2323/4885ALDH1A1 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.